Nogo-B receptor deficiency causes cerebral vasculature defects during embryonic development in mice  by Rana, Ujala et al.
Developmental Biology 410 (2016) 190–201Contents lists available at ScienceDirectDevelopmental Biologyhttp://d
0012-16
n Corr
Children
Road, M
nn Cor
Biology
Milwau
E-m
qmiao@
1 Cojournal homepage: www.elsevier.com/locate/developmentalbiologyGenomes and developmental controlNogo-B receptor deﬁciency causes cerebral vasculature defects during
embryonic development in mice
Ujala Rana a,b,d,1, Zhong Liu a,b,d,1, Suresh N. Kumar b,d, Baofeng Zhao a,b,d, Wenquan Hu a,b,d,
Michelle Bordas c,d, Stephanie Cossette c,d, Sara Szabo b,d, Jamie Foeckler f,h,
Hartmut Weiler f,h, Magdalena Chrzanowska-Wodnicka h, Mary L. Holtz e,
Ravindra P. Misra e, Valerie Salato b,d, Paula E. North b,d, Ramani Ramchandran c,d,g,nn,
Qing Robert Miao a,b,d,n
a Division of Pediatric Surgery, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, USA
b Division of Pediatric Pathology, Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
c Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI 53226, USA
d Children's Research Institute, Medical College of Wisconsin, Milwaukee, WI 53226, USA
e Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA
f Department of Physiology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
g Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA
h BloodCenter of Wisconsin, Milwaukee, WI 53226, USAa r t i c l e i n f o
Article history:
Received 6 July 2015
Received in revised form
21 December 2015
Accepted 21 December 2015
Available online 31 December 2015x.doi.org/10.1016/j.ydbio.2015.12.023
06/& 2016 Elsevier Inc. All rights reserved.
esponding author at: Department of Surgery a
's Research Institute, Medical College of Wisc
ilwaukee, WI 53226, USA.
responding author at: Department of Pediat
Program, Children's Research Institute, Me
kee, WI 53226, USA.
ail addresses: rramchan@mcw.edu (R. Ramcha
mcw.edu (Q.R. Miao).
ntribute equally to this work.a b s t r a c t
Nogo-B receptor (NgBR) was identiﬁed as a receptor speciﬁc for Nogo-B. Our previous work has shown
that Nogo-B and its receptor (NgBR) are essential for chemotaxis and morphogenesis of endothelial cells
in vitro and intersomitic vessel formation via Akt pathway in zebraﬁsh. Here, we further demonstrated
the roles of NgBR in regulating vasculature development in mouse embryo and primitive blood vessel
formation in embryoid body culture systems, respectively. Our results showed that NgBR homozygous
knockout mice are embryonically lethal at E7.5 or earlier, and Tie2Cre-mediated endothelial cell-speciﬁc
NgBR knockout (NgBR ecKO) mice die at E11.5 and have severe blood vessel assembly defects in embryo.
In addition, mutant embryos exhibit dilation of cerebral blood vessel, resulting in thin-walled endothelial
caverns. The similar vascular defects also were detected in Cdh5(PAC)-CreERT2 NgBR inducible ecKO
mice. Murine NgBR gene-targeting embryonic stem cells (ESC) were generated by homologous re-
combination approaches. Homozygous knockout of NgBR in ESC results in cell apoptosis. Heterozygous
knockout of NgBR does not affect ESC cell survival, but reduces the formation and branching of primitive
blood vessels in embryoid body culture systems. Mechanistically, NgBR knockdown not only decreases
both Nogo-B and VEGF-stimulated endothelial cell migration by abolishing Akt phosphorylation, but also
decreases the expression of CCM1 and CCM2 proteins. Furthermore, we performed immunoﬂuorescence
(IF) staining of NgBR in human cerebral cavernous malformation patient tissue sections. The quantitative
analysis results showed that NgBR expression levels in CD31 positive endothelial cells is signiﬁcantly
decreased in patient tissue sections. These results suggest that NgBR may be one of important genes
coordinating the cerebral vasculature development.
& 2016 Elsevier Inc. All rights reserved.nd Department of Pathology,
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ndran),1. Introduction
The blood vessel (BV) formation and maturation is critical
during embryogenesis (Jain, 2003). It involves the coordinated
development of two cell types – endothelial cells (EC) and vascular
smooth muscle cells (SMC) (Benjamin et al., 1999; Bergers and
Song, 2005; Evensen et al., 2009). Blood vessels plexus is the ﬁrst
functioning system in a developing embryo, lending support to the
developing organ systems by transporting nutrients, growth fac-
tors and gases (Herbert and Stainier, 2011). The BV development
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called vasculogenesis, followed by sprouting of new vessels from
the existing ones, a process called angiogenesis (Geudens and
Gerhardt, 2011; Herbert and Stainier, 2011; Kliche and Walten-
berger, 2001; Patan, 2000; Risau, 1997). Migration and prolifera-
tion of EC play important roles during BV sprouting (Lamalice
et al., 2007). The developing BVs are guided by local cues for mi-
gration, and prominent one among these factors is vascular en-
dothelial growth factors (VEGF) (Coultas et al., 2005; Gerhardt,
2008; Kowanetz and Ferrara, 2006; Li et al., 2008). VEGF act as a
chemoattractant, by interacting with VEGF receptors (VEGFR) on
the tip of EC and initiates a signal cascade via activation of Akt and
Erk kinases (Cleaver and Krieg, 1998; Evensen et al., 2009; Lin
et al., 2007). The integrity of developing vascular structure is
maintained by EC junctions (Dejana and Orsenigo, 2013), which
are the points where EC contact with each other. There are two
types of junctions, tight junctions and adherens junctions (Dejana
and Orsenigo, 2013). Decreased junction stability may lead to he-
morrhage and vascular lesions (Dejana and Orsenigo, 2013; Nies-
sen et al., 2011; Vestweber et al., 2010, 2009). Abnormal vascu-
larization in the ﬁrst half of developmental period may results in
lethality or ischemic diseases (Krebs et al., 2010). Cerebral ca-
vernous malformations (CCMs) are abnormal clusters of thinner
and dilated blood vessels called caverns (Draheim et al., 2014;
Fischer et al., 2013; Zheng et al., 2012) that are ﬁlled with blood
(He et al., 2010; Kleaveland et al., 2009; Whitehead et al., 2004).
CCM affects up to 0.5% of the population (Al-Shahi Salman et al.,
2012; Haasdijk et al., 2012), leading to seizures and stroke with
symptoms, including hemorrhages and headache. Loss-of-function
of three genes CCM1, CCM2 and CCM3 are associated with onset of
this disease (Bergametti et al., 2005; Boulday et al., 2011; Du-
bovsky et al., 1995; Liquori et al., 2003). Several signaling pathways
such as Erk, Akt, Rap1 and RhoA GTPases have been implicated in
the pathogenesis of CCM (Bazzoni and Dejana, 2004; Dibble et al.,
2010; Ma et al., 2007; Schleider et al., 2011; Wilhelm et al., 2006),
but the exact link between these CCM proteins and their expres-
sion regulation still remains to be established. Here, we identify
NgBR as a previously unidentiﬁed player in regulating CCM1 and
CCM2 expression in endothelial cells as well as cerebral vascu-
lature development.
Previous results show that Nogo-B is the major isoform of Nogo
in blood vessels, and is highly expressed in both endothelial cells
(EC) and smooth muscle cells (SMC) (Acevedo et al., 2004). Amino
terminus of Nogo-B (AmNogo-B) promotes the migration of both
EC and SMC (Acevedo et al., 2004). Mice deﬁcient in Nogo-A/B
show exaggerated neointimal proliferation, abnormal remodeling
and a deﬁcit in ischemia induced arteriogenesis and angiogenesis
(Yu et al., 2009). Nogo-B receptor (NgBR) was identiﬁed as a re-
ceptor speciﬁc for AmNogo-B by an expression cloning approach.
High afﬁnity binding of AmNogo-B to NgBR is essential for Am-
Nogo-B mediated chemotaxis and tube formation of EC (Miao
et al., 2006). We have shown that NgBR is also essential for VEGF-
induced chemotaxis and morphogenesis of EC cells in vitro, and BV
formation in zebraﬁsh via Akt pathway (Miao et al., 2006; Zhao
et al., 2010). Here, we demonstrate that NgBR deﬁciency in EC
decreases the expression of both CCM1 and CCM2 genes, and re-
sults in cerebral vascular defects in NgBR endothelial cell speciﬁc
knockout (ecKO) mice. Our study suggests that NgBR plays an
important role in regulating EC dynamics during cerebral blood
vessel development.2. Materials and methods
2.1. Materials and reagents
Anti-NgBR rabbit polyclonal antibody was generated as de-
scribed in our previous publication (Zhao et al., 2010). Anti-total
ERK, Akt, phos-Akt, and phos-Erk antibodies were purchased from
Cell Signaling Technology (Beverly, MA). Anti-Hsp90 antibody was
purchased from BD Biosciences (San Jose, CA). Anti-CCM1, CCM2
and CCM3 antibodies were purchased from Acris (San Diego, CA).
Non-silencing (NS) control siRNA and siRNAs targeting NgBR were
purchased from QIAGEN (Frederick, MD). Tek-Cre (Tie2-Cre) (stock
number 008863), ROSA26Sor-lacZ (stock number: 003474), and
ROSA26Sor-EYFP (stock number: 006148) mice were purchased
from Jackson laboratory (Bar harbor, Maine), and β-actin Cre
mouse (Lewandoski et al., 1997) was a generous gift from Dr. Ka-
therine Shim (Children's Research Institute, MCW). Cdh5(PAC)-
CreERT2 mice were transferred from Dr. Ralf Adams (Cancer Re-
search UK).
2.2. Mouse experiments
The mice were housed in the Medical College of Wisconsin
Biological Resource Center. The Institutional Animal Care and Use
Committee at the Medical College of Wisconsin approved the
procedures performed here. For generating NgBR global knockout,
we used β-actin Cre line (Lewandoski et al., 1997). For timed
pregnancies, female mouse (NgBR ﬂox/ﬂox, NgBRﬂ/ﬂ) was caged
with male (Cre positive NgBR ﬂox/WT, NgBRﬂ/WT:Cre) in the eve-
ning; following morning pregnancy was established by the pre-
sence of vaginal plug (embryonic stage 0.5). Embryos were col-
lected at E6.5, 7.5, 8.5 for β-actin Cre experiments. For the en-
dothelial-speciﬁc loss of NgBR, embryos were collected from NgBR
ﬂox/ﬂox females mated to Tie2Cre positive (Jackson laboratory,
USA) NgBR ﬂox/WT males. Embryos were collected at E8.5, E9.0,
E9.5, E10.5, E11.5 and E13.5. For temporal loss of NgBR in en-
dothelial cells speciﬁcally, we used Cdh5(PAC)-CreERT2-positive
NgBR ﬂox/WT males to mate with NgBR ﬂox/ﬂox females. NgBR
knockout was activated by injecting pregnant females with 2 mg
of tamoxifen (T5648, Sigma Aldrich, St. Louis, MO) at E8.5 and
harvested embryos at E10.5. To conﬁrm Cre efﬁciency, we used
NgBR ﬂox/ﬂox:LacZ/LacZ (NgBRﬂ/ﬂ:LacZ/LacZ) females to mate with
heterozygous males (NgBRﬂ/ﬂ:Cre). Littermate embryos were used
as controls for each animal experiment. Mixed backcrossed ani-
mals were used for β-actin Cre and Tie2Cre experiments, and
C57BL/6 backcrossed animals were used for Cdh5(PAC)- CreERT2
experiments.
2.3. Whole mount immunoﬂuorescence staining
Embryos were harvested at E10.0 dpc and ﬁxed in 4% (wt/vol)
paraformaldehyde overnight. The following day, embryos were
washed with PBST (0.1% tween-20 in PBS) and dehydrated in as-
cending series of methanol in PBST for 10 min each. The embryos
were bleached with Dent's bleach (64% Methanol and 16% DMSO)
for 3 h and were rehydrated via graded methanol series. Embryos
were blocked overnight with 5% (wt/vol) normal serum in PBST
(PBSST) at 4 °C. Following day, embryos were incubated with PE-
CAM-1 antibody (BD Biosciences, San Jose, CA) in PBSST for 2 days.
Embryos were washed and incubated with secondary antibody
overnight at 4 °C, followed by overnight PBST washes. Embryos
were ﬁxed with 4% (wt/vol) paraformaldehyde for 2 h before
imaging. Confocal images were taken with Carl Zeiss LSM 510
microscope using AIM4.2 software and processed using auto-
measure plus module of AxioVision 4.8 ver (Zeiss).
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NgBR ﬂoxed E14Tg2a 129/Ola embryonic stem cells (ESCs) were
generated by homologous recombination of a targeting vector in
which LoxP sites ﬂank NgBR exons 2 and 4. Correct gene targeting
was conﬁrmed by Southern blot analysis of genomic DNA isolated
from established ES cells. E14Tg2a 129/Ola ESCs are feeder-in-
dependent, and cultured in GMEMmedium (Sigma Aldrich, St. Louis,
MO) supplemented with 2 mM glutamine (Invitrogen, Carlsbad, CA),
1 mM sodium pyruvate (Invitrogen), 1x nonessential amino acids,
10% (v/v) fetal bovine serum (characterized, Hyclone, Canada), beta-
mercaptoethanol (Sigma Aldrich), and 1000 units per ml of leuko-
cyte inhibitor factor (LIF) (Chemicon, Temecula, CA). Heterozygous
knockout of NgBR in ESCs was generated by transfecting Cre-GFP
plasmid DNA and sorted based on positive GFP expression. To gen-
erate embryoid bodies, 300 ES cells in 10 μl of ES cell growth
mediumwithout LIF were added to the lid of Petri dish and cultured
in hanging drops for 2 days. Subsequently, the aggregates were
cultured in suspension in Petri-dish containing ES medium without
LIF for 4 days and then seed in 1 mg/ml Collagen type I gel (about
2 mm thick) in 24 well plate without LIF and in the presence of VEGF
(50 ng/ml) for another 11 days. The differentiated EB were ﬁxed
using 4% paraformaldehyde in PBS and permeabilized with 0.1%
Triton X-100 in TBS (TBS-T). After blocking in 5% horse serum plus
1% BSA, the ﬁxed EB was incubated with primary antibodies against
murine PECAM-1 (BD Biosciences, San Jose, CA) at 4 °C overnight
and developed with corresponding Alexa-Fluor 594 ﬂuorescence-
conjugated second antibody (Molecular Probes, Eugene, OR). Cell
nuclei were counterstained with 20 g/mL Hoechst 33342 (Sigma
Aldrich). Extent of blood vessel sprouting was analyzed by a confocal
laser-scanning microscope (Zeiss LSM 510 META) and analyzed by
axiovison software aided 3D rendering.
2.5. LacZ staining
As a control for LacZ stained KO embryos, Tie2Cre transgenic
mice were bred with ROSA26Sor-LacZ female. β–galactosidase
(LacZ) staining was performed according to previous reports
(Loughna and Henderson, 2007). Brieﬂy, at E10.5, embryos were
harvested and ﬁxed with 4% (wt/vol) paraformaldehyde and 0.2%
(vol/vol) glutaraldehyde for 15 min at 4 °C. After washing for
5 min, embryos were stained with 1% (wt/vol) X-gal (Invitrogen)
solution for 6 h at 37 °C. To generate endothelial-restricted, LacZ
positive NgBR KO animals, Tie2Cre-NgBRﬂ/wt males were bred with
LacZ/LacZ:NgBRﬂ/ﬂ females. At E10.5, embryos were harvested and
processed as described above. Olympus stereomicroscope with
DP-72 camera and cellsens 1.8 software was used for capturing
and processing images, respectively. After staining, embryos were
ﬁxed with 4% (wt/vol) paraformaldehyde overnight and were
processed for parafﬁn sectioning.
2.6. Human tissue samples
Human infantile hemangioma and human cerebral cavernous
malformation tissue specimens from Pediatric BioBank at the
Children's Hospital of Wisconsin Research Institute are anon-
ymous. Research on human patient samples were performed ac-
cording to the Medical College of Wisconsin-approved institu-
tional review Board protocols, and informed consent was obtained
in accordance with the declaration of Helsinki.
2.7. Data analysis
Data are presented as mean7the standard error of the mean
(SEM). The statistical signiﬁcance of differences was evaluated
with the ANOVA analysis. Signiﬁcance was deﬁned as Po0.05.3. Results
3.1. NgBR expression in adult mouse tissue
Previous studies have shown that Nogo-B, ligand to NgBR, is
the only Nogo isoform that was expressed in the blood vessels
(Acevedo et al., 2004; Miao et al., 2006). Hence, as an overture to
the phenotypic studies of NgBR, we set forth to understand the
expression of NgBR in murine tissues, with respect to Nogo-B.
Immunohistochemical evaluation of adult mouse tissues (4 week
old) shows that NgBR is speciﬁcally expressed in both smooth
muscle cells (SMC) and endothelial cells (EC) of aorta (Fig. 1A).
NgBR expression is negative in embryonic and adult hematopoietic
cells except for megakaryocyte (data not shown). NgBR expression
in brain is restricted to the blood vessels whereas in kidney, NgBR
is expressed in both tubules and BV. Glomeruli in kidney are ne-
gative for NgBR expression. Speciﬁcity of NgBR expression in BV is
consistent in heart as staining is positive in BV whereas cardio-
myocytes are negative. NgBR Immunohistochemistry staining on
human tissue section of a benign vascular neoplasm, infantile
hemangioma that is abundant in vasculature showed that NgBR is
speciﬁcally expressed in both SMC and EC (Fig. 1B). Localization of
NgBR expression is highly consistent with its ligand, Nogo-B, (Fig.
S1). The immunohistochemistry results conﬁrmed that NgBR is
highly expressed in both SMCs and ECs of blood vessels.
3.2. NgBR global knockout results in early embryonic lethality
To determine the role of NgBR in mammalian embryogenesis,
we bred NgBRﬂ/ﬂ mice with β-actin Cre mice that ubiquitously
expresses Cre gene (Mahoney Rogers et al., 2011) (Fig. 1C). After
breeding heterozygous Cre male (NgBRﬂ/WT:β-actin Cre) with
homozygous females (NgBRﬂ/ﬂ), the embryos were harvested at
E7.5. Genotyping results revealed that heterozygous (NgBRﬂ/WT:β-
actin Cre) and control (NgBRﬂ/ﬂ: no β-actin Cre) embryos were
viable whereas knockout embryos (NgBRﬂ/ﬂ: β-actin-Cre) did not
survive, as indicated by empty decidua (Fig. 1D). The disparity
from Mendelian ratios of 1:2:1 (25%:50%:25%) at E7.5 further
supports our conclusion that global loss of NgBR results in the
embryonic lethality (Fig. 1E). The results indicate that NgBR is vital
for early embryonic development (gastrulation) and could be a key
molecule in later stages of embryonic development.
3.3. NgBR knockout in endothelial cells induces early embryo
lethality
Because of robust expression of NgBR in the vasculature (Fig. 1),
and embryonic lethality associated with NgBR global knockout
mice, we investigated the effect of NgBR loss selectively in the ECs
of the vasculature during embryonic development. We bred
NgBRﬂ/ﬂ mice with Tie2Cre mice. Tie2Cre mice are endothelial and
hematopoietic cells-speciﬁc Cre mice, where the tie2 promoter
drives Cre expression, which begins around E7.5 (Kisanuki et al.,
2001). The speciﬁcity of Cre activity was conﬁrmed by using YFP
reporter mice (ROSA26Sor-EYFP), where NgBRﬂ/ﬂ:YFP/YFP female
mice was bred with heterozygous Tie2Cre male mice. Positive YFP
signal speciﬁcally in BV conﬁrms that Cre is highly expressed in
endothelial cells (Fig. 2B, showing brain region as indicated in
Fig. 2A box), which supports the conclusion of endothelial speciﬁc
loss of NgBR because NgBR is not expressed in embryonic blood
cells. The NgBR Tie2Cre endothelial cell speciﬁc knockout mice
(ecKO) exhibit embryonic lethality at E10.5–11.5, whereas het-
erozygous NgBR ecKO embryos are viable (Fig. 2A and C). Although
no change in somite count was observed among mutant and
control littermate embryos (Fig. S3), homozygous ecKO embryos
are smaller in size as compared to the littermate control (Fig. 2A).
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Fig. 1. NgBR expression in adult mouse tissues. (A) Immunohistochemistry of NgBR on parafﬁn embedded adult mouse tissue. NgBR is speciﬁcally expressed in blood vessels
in aorta, heart, brain and kidney. Scale bar¼200 mm. (B) NgBR expression in blood vessel. NgBR expression in smooth muscle cells is stronger than endothelial cells. Scale
bar¼50 mm. (C) NgBR was knocked out globally in the developing embryo by β-actin Cre. Homozygous ﬂoxed female was bred with heterozygous male (ﬂox/WT:Cre/WT).
(D) At E7.5, no NgBR KO embryo was harvested because the decidua is empty in NgBR KO embryos (b,d). (E) The statistical analysis of embryo lethality exhibits that no live
KO embryos were available beyond E7.5.
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generating NgBR conditional gene targeting mice with Rosa26-LacZ
reporter gene (ﬂox/ﬂox:LacZ/LacZ). When bred with Tie2cre mice, β-
galactosidase staining of the embryos, at E10.5, conﬁrmed Cre ac-
tivity speciﬁcally in BV. As a negative control for comparing the effect
of EC-speciﬁc NgBR KO on BV assembly, we also bred homozygousLacZ female mice with Tie2Cre male. At E10.5, the embryos harvested
from this breeding were stained for β-galactosidase as described in
the Methods. In Fig. 2D, LacZ staining results show that a well-pat-
terned (tree-like) major cerebral arteries branching and spreading
evenly in the developing brain (black arrows) were presented in
control embryos at E10.5. However, LacZ stained BV in E10.5 mutant
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Fig. 2. NgBR ecKO in developing embryo exhibits lethality at E11.5. (A) NgBR ecKO embryo at E10.0. As pointed by arrows, Tie2Cre-NgBRﬂ/ﬂ (NgBRECKO) embryo yolk sac
(c) showed minimal BV development as compared to NgBRﬂ/ﬂ (WT) (a). The box around the cerebral region highlights the region shown in panel B. (B) Confocal images of
whole mount PECAM-1 staining shows blood vessel patterning in control and mutant E10.5 embryos. Positive YFP staining in mutant embryo (NgBRECKO:YFP) shows that the
Cre is active and speciﬁc in blood vessels. Control embryos (WT:YFP) show negative YFP signal. (C) Statistical analysis of embryo lethality. NgBR ecKO embryo start to die
around E10.5 and no alive KO embryo was recovered post E11.5. (D) LacZ staining conﬁrms Cre activity in E10.5 embryo. Tie2Cre-LacZ (Control) embryo shows well-
developed cerebral BV; inversely NgBRECKO: LacZ embryo exhibits truncated and dilated BV in the brain. Arrow points at the developing BV in WT brain and aberrant BV in
KO brain. Scale bar¼1 mm. (E) Parafﬁn sections (4 mm) of LacZ stained embryos at E10.5. Blue LacZ staining indicates that Cre activity is speciﬁc for endothelium. Arrows
mark dilated vessels in KO. Scale bar¼100 mm.
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Fig. 3. Whole mount PECAM-1 IF staining shows aberrant BV assembly in the brain of NgBR ecKO embryo. (A) Whole embryo (E10.0) was stained with PECAM-1 antibody to
observe BV assembly in the embryo. NgBRECKO brain exhibited a dilated and defective-patterned cerebral arteries (pointed by white arrows) and sprouting BVs. (B) Brain
vasculature of WT and NgBRECKO at a higher magniﬁcation showing dilation of vessels in NgBRECKO. Scale bar¼100 μm. (C) Immunohistochemical staining of PECAM-1 on
parafﬁn sections of E10.5 embryo shows dilated and poorly developed BV in the brain of NgBR ecKO (b) as compared to control (a). (c) and (d) shows aberrant BV in higher
magniﬁcation. Scale bar¼200 μm. (D) Quantiﬁcation of blood vessel area of mutant and control embryos at E10.5 using image J software. *Po0.05 (n¼15). Increased vessel
area in mutant embryo conﬁrms vasodilation.
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pattern of BV as shown in control mice, cerebral BV of NgBR ecKO
mice are irregular and truncated. To further characterize these vessel
defects, we closely examined transverse parafﬁn sections of LacZ
stained embryos that were counterstained with nuclear fast red
staining. Fig. 2E shows cerebral blood vessels near eye region in NgBR
ecKO embryo are dilated and exhibit disrupted organization. These
results indicate that NgBR expression in EC is essential for cerebral
blood vessel assembly and embryonic viability during development.
3.4. NgBR endothelial cell speciﬁc KO causes defective cerebral BV
patterning and dilation
To investigate the majority of the embryonic vasculature, we
performed whole-mount immunoﬂuorescent staining using PECAM-
1 antibody, an EC marker. After staining, embryos were cleared with
BBB solution (benzyl benzoate/benzyl alcohol) and were imaged
using confocal microscopy. Reconstructed 3D images show that unlike
a well-organized tree-like patterning presented in littermate control,
cerebral blood vessel assembly of NgBR ecKO mice is consistently
truncated and exhibit disrupted organization (Fig. 3A). As shown in
littermate WT control, a communicating artery connects the two
major middle cerebral arteries (pointed by arrow) (Fig. 3A left panel,
movie 1). In NgBR ecKO heterozygous embryo (movie 2), the com-
municating artery is lost but surprisingly little patterning defect of the
middle cerebral arteries was observed. In NgBR ecKO homozygous
embryos, the communicating artery was also lost but in addition,
disruption of major artery patterning was observed (Fig. 3A right
panel, movie 3). At higher magniﬁcation, cerebral blood vessels in
mutant embryos are highly dilated (pointed by arrows) as compared
to their littermate controls (Fig. 3B). We also performed PECAM-1
immunohistochemical (IHC) staining on serial transverse parafﬁn
sections of mutant and control littermate embryos (E10.5). PECAM-1IHC staining results revealed that BV in NgBR ecKO mice is dilated
whereas BV in control WTmice is smaller in diameter (Fig. 3C). Image
J was used for quantiﬁcation of BV area. The results (Fig. 3D) further
conﬁrmed that the blood vessels in mutant embryos are dilated as
compared to control embryos. In order to characterize the mutant
vessels closely, we performed PECAM-1 immunoﬂuorescence staining
on E8.5 and E9.5 embryos (Fig. S4). Results show that no BV differ-
ences in mutant and control embryos were appreciated at E8.5,
whereas by E9.5 we start observing the dilation of mutant vessels
(Fig. S4). Further, as compared to control, mutant embryos are smaller
in size, but have the identical somite numbers. Cardiac development
of mutant and control embryos was also examined at different stages
of development (E9.0, E9.5, E10.5) and no obvious defect was ob-
served (Fig. S5). In addition, no obvious bronchial arch artery defects
were observed in mutant embryos (Fig. S5). During these stages, mice
with loss of NgBR expression in EC have completed cardiac looping,
and show appropriate myocardial trabeculation. In addition, we as-
sessed BV proliferation by double immunoﬂuorescent (IF) staining of
Isolectin B4, a glycoprotein that stains EC, and phosphorylated histone
3 (phos-H3). As shown in Fig. S6, there is no difference in EC pro-
liferation in mutant and control embryos.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.ydbio.2015.12.023
3.5. NgBR endothelial cell speciﬁc KO exhibits yolk sac vasculature
defect later than E9.0
Yolk sac is a major embryonic vascularization site in the de-
veloping embryo. In fact, the ﬁrst BVs observed in yolk sac are
important for providing nutrients to the growing embryo (Garcia
and Larina, 2014). To exclude the possibility that BV dilations in
the brain are not secondary to defective yolk sac development, we
performed whole mount PECAM-1 staining on yolk sac from E9.0
U. Rana et al. / Developmental Biology 410 (2016) 190–201 197and E10.0 embryos. E9.0 control, heterozygous and homozygous
NgBR ecKO yolk sac does not exhibit any disruption in BV assembly
(Fig. 4A). On the contrary, at E10.0, mutant yolk sac displays
aberrant BV development as opposed to control and heterozygous,
which still maintains a well-organized BV structure (Fig. 4B). These
results consolidate the fact that the cerebral BV assembly defect in
mutant embryo is a direct consequence of NgBR deﬁciency in EC.
3.6. BV defects in NgBR inducible endothelial cell speciﬁc knockout
mice
Since EC and hematopoietic cells have common origin, one of
the concerns for using Tie2Cre model is the fact that Tie2 is also
expressed in hematopoietic cells (Kisanuki et al., 2001). Although
NgBR is not expressed in embryonic blood cells, we decided to
complement our Tie2Cre with Cdh5(PAC)-CreERT2 line, where CreW T
CDH5(PAC)-CreERT2: LacZ
W T
Fig. 5. Inducible Cdh5-Cre conﬁrms BV defect due to loss of NgBR in EC. (A) LacZ stained
mother at E 8.0. Positive blue staining around blood vessel conﬁrms that the Cre is spe
analysis of E9.5 yolk sac after tamoxifen injection at E8.0. The transcripts of NgBR decreas
to housekeeping gene GAPDH. The result conﬁrms that the tamoxifen injection is efﬁ
ﬂuorescence staining of E10.5 embryo after tamoxifen injection at E8.5. The PECAM-1
dilated and defective-patterned. Scale bar¼200 μm.is under the control of the VE-cadherin (cdh5) promoter (Wang
et al., 2010). The CreERT2 also allows for temporal regulation of
the Cre enzyme thereby achieving both temporal and spatial de-
pletion of NgBR. We bred NgBRﬂ/ﬂ mice with Cdh5(PAC)-CreERT2
mice from Dr. Ralf Adams, Cancer Research UK (Wang et al., 2010).
The Cre was activated in embryos via intraperitoneal injection of
tamoxifen (2 mg) to pregnant mothers at different gestational
stages. Fig. 5A shows that when pregnant mother (LacZ/LacZ fe-
male mated with Cdh5(PAC)-CreERT2 male) is injected with ta-
moxifen at E8.5, the Cre is speciﬁcally activated in the endothelial
cells of BV, as shown by positive LacZ staining. Lack of positive
LacZ staining in blood cells conﬁrmed that Cdh5(PAC)-CreERT2 is
not expressed in hematopoietic cells.
NgBRﬂ/ﬂ females were bred with NgBRﬂ/ﬂ:Cdh5(PAC)-CreERT2
males. The pregnant females were injected with tamoxifen once at
E8.5 and embryos were harvested at E10.5. NgBR gene knockoutNgBR iECKO
NgBR  iECKO
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E9.5 embryo parafﬁn transverse section. Tamoxifen injection was given to pregnant
ciﬁc for EC. Blood cells are negative for blue LacZ staining. (B) Real-time PCR array
es in NgBR inducible ecKO yolk sac. Data are presented as change fold as normalized
cient in depleting NgBR in mutant embryos (NgBRiECKO). (C) PECAM-1 immuno-
staining shows that unlike control, cerebral blood vessels in mutant embryos are
U. Rana et al. / Developmental Biology 410 (2016) 190–201198was conﬁrmed by real-time PCR (Fig. 5B). Unlike littermate control
and heterozygous embryos, mutant embryos are smaller size and
exhibit aberrant cerebral BV patterning. Results of PECAM-1 IF
staining on serial transverse sections (Fig. 5C) show that mutant
embryos have dilated and disrupted organization of BV as opposed
to a well-organized BV in control littermate, which are consistent
with defects observed in Tie2Cre model (Fig. 3C). In addition, we
have included 3D image of transverse section of cerebral BV (Fig.
S7A). We also used Cdh5-Cre model, an endothelial cell speciﬁc
Cre, to generate NgBR mutant embryos at E12.5. The 3D image of
whole mount PECAM-1 IF staining (Fig. S7C) shows dilated cere-
bral BV in the brain of NgBR mutant embryos. Results from two
different endothelial cell speciﬁc Cre models demonstrate that
NgBR deﬁciency in EC results in dilated and poorly organized BV
assembly in the developing brain, which are reminiscent of dilated
blood vessels presented in cerebral cavernous malformation (CCM)
(Whitehead et al., 2004).
3.7. NgBR deﬁciency impairs the primitive blood vessel formation in
embryoid bodies
Interestingly, similar vascular defects have been recapitulated
in vitro 3D embryonic culture system. Embryoid bodies were
generated by culturing embryonic stem cells (ESCs) in hanging
drops for 2 days, subsequently, the aggregates were cultured in
suspension in ES medium without leukemia inhibitory factor (LIF)
for 4 days and then seed in 1 mg/ml Collagen type I gel (about
2 mm thick) without LIF and in the presence of VEGF (50 ng/mL)
for another 11 days as shown in Fig. 6A. PECAM-1 whole mount
staining was used to determine blood vessel formation. Homo-
zygous NgBR knockout embryonic stem cells (ESC) do not survive
because NgBR plays a vital role in early embryonic development.
The genotyping results from ESC culture shows that homozygous
knockout ESC cells were sorted and cultured but by day 3 these2 days 4 days+LIF -LIF
-LIF+VEG F
Day 0ESC -EB
3D collagen g
WT NgBR +/-
Fig. 6. Effects of NgBR deﬁciency on the primitive blood vessel formation in embryoid bo
stem cell media containing LIF, which prevents the differentiation of ESCs. EB were form
collagen gel and was allowed to develop blood vessel structure in 15 days by removin
PECAM-1 IF staining. (B) Immunoﬂuorescence PECAM-1 staining of NgBR WT and hetero
whereas heterozygous exhibits truncated and dilated BV structure. (D) Quantiﬁcation of
(n¼3). Decreased branching point in heterozygous knockout highlights poorly formedcells were ﬂoating in the media (Fig. S8). EB derived from het-
erozygous NgBR knockout ESC exhibit defective BV development,
supporting our in vivo observation that NgBR could regulate EC
dynamics and is required for BV formation. Fig. 6B shows that
unlike wild-type control (Fig. 6B, left panel, movie 4), hetero-
zygous NgBR knockout EB (Fig. 6B, right panel, movie 5) exhibits
dilated and truncated EC tubes, which have much less branching
and fail to develop into a tree-like structure. The quantitative re-
sults of branching points from both wild-type control and het-
erozygous NgBR knockout EB are shown in Fig. 6C. This result
highlights that NgBR has a critical role in regulating blood vessel
formation during embryonic development.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.ydbio.2015.12.023
3.8. NgBR deﬁciency inhibits migration of HBMVECs in vitro
BV development relies heavily on ability of EC to respond to
local cues (chemoattractant such as VEGF) and perform functions
such as migration and proliferation. To understand how NgBR
deﬁciency can affect brain EC functions i.e. migration and activa-
tion in response to chemoattractant such as VEGF and AmNogo-B,
an NgBR speciﬁc ligand (Miao et al., 2006), we chose human brain
microvascular endothelial cells (HBMVEC). In order to determine
the effects of NgBR deﬁciency on HBMVECs migration, we con-
ducted modiﬁed Boyden chamber migration experiments.
HBMVECs cells were transfected with non-silencing control siRNA
(NS) and validated siRNA targeting NgBR (siNgBR) (Miao et al.,
2006). 1105 number of cells of NS and siNgBR HBMVECs were
added in each transwell coated with 1% collagen. The transwells
were placed in the chambers containing basal media (control), or
basal media containing either VEGF (100 ng/mL) or 100 nM Am-
Nogo-B. As shown in Fig. S9A, both VEGF and AmNogo-B induced
the migration of HBMVECs. NgBR deﬁciency reduced either VEGFPECAM - 1 staining
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Prim itive blood vessels
el
WT NgBR+/-
0
10
20
30
40
dleifrep
st ni o
P
hcnar
B
*
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g LIF and adding VEGF (50 ng/ml). Established blood vessels were determined by
zygous EB blood vessel structure. WT exhibit tree-like well-developed BV network
branching points of wild-type and heterozygous knockout blood vessels. *Po0.05
BV structure.
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respective controls. The result implicates that NgBR deﬁciency
prevents EC migrating towards local cues and results in defective
tube like structure and/or BV patterning during blood vessel
development.
Given the observed migration defects in NgBR deﬁcient ECs, we
further determined the effects of NgBR deﬁciency on the EC acti-
vation by detecting the phosphorylation of Akt and ERK, which are
major signaling pathways attributed to the migration of ECs
(Shiojima and Walsh, 2002). Fig. S9B and C shows that both VEGF
and AmNogo-B stimulate the phosphorylation of Akt and Erk in
quiescent HBMVECs. NgBR deﬁciency diminishes the VEGF and
AmNogo-B-stimulated phosphorylation of Akt and Erk as com-
pared to the respective controls (Fig. S9B and C). These results
suggest that NgBR is an essential player in EC response to VEGF
and AmNogo-B.4. Discussion
NgBR was discovered as a receptor for Nogo-B (Miao et al.,
2006). Earlier studies have revealed that Nogo-B is the only iso-
form of Nogo-family that is expressed in blood vessels, and regu-
lated EC and SMC adhesion and migration (Acevedo et al., 2004;
Miao et al., 2006). Several lines of evidence suggest that NgBR is
required for chemotactic actions of Nogo-B and VEGF, and is re-
quired for migration of EC (Miao et al., 2006). Zebraﬁsh studies
have shown that NgBR is required for intersomitic vessel (ISV)
formation (Zhao et al., 2010), which further emphasizes the vital
role of NgBR in vascular development. However, the roles of NgBR
in mammalian development are currently unknown. In this study,
we demonstrate the essential role of NgBR in mouse vasculature
development.
The earliest defects in mice lacking NgBR results in lethality
during gastrulation, implicating that NgBR could be a key regulator
of pathways that are building blocks of life such as stem cell dif-
ferentiation and angioblast migration. The vascular defects are ob-
served in mice lacking NgBR speciﬁcally in EC, in both Tie2-Cre and
inducible Cdh5-Cre models. The mutant embryo fails to survive
beyond E11.0 and exhibits impaired cerebral BV assembly as well as
dilation of cerebral blood vessels, resulting in thin-walled, en-
dothelial caverns that are redolent of cerebral cavernous mal-
formation. These vascular defects in NgBR ecKO mice indicate that
NgBR could be the key to unravel the pathogenesis of vascular
anomalies. The vascular defects are associated with the inability of
NgBR deﬁcient EC to migrate towards chemoattractants such as
VEGF and/or AmNogo-B (Miao et al., 2006; Zhao et al., 2010). We
also demonstrated that NgBR-mediated EC migration is dependent
on Akt activation, which is vital for VEGF signaling pathway (Zhao
et al., 2010). Constitutively activated Akt can rescue the vascular
anomaly in NgBR deﬁcient zebraﬁsh (Zhao et al., 2010). We observed
similar effect in HBMVECs, where NgBR deﬁciency impairs the
phosphorylation of Erk and Akt. The defects of cerebral BV assembly
could possibly be due to reliability of brain on angioblast migration
for building up BV (Schmidt et al., 2007). Brain could be speciﬁcally
affected since it lacks resident angioblast and relies heavily on VEGF
signaling for angioblast migration and cerebral blood vessel devel-
opment (Bautch, 2011). Therefore, these defects of BV assembly in
the brain of NgBR ecKO mice could be due to the disruption of an-
gioblast or EC migration in a developing embryo because NgBR is
essential for both VEGF and AmNogo-B-stimulated phosphorylation
of Erk and Akt. Our results indicate that NgBR plays a pivotal role
during cerebral blood vessel assembly and could be a key player in
governing EC patterning and tube formation.
The cerebral blood vessel dilation observed in NgBR mutant
embryos bears resemblance to defects observed in CCM genemutant mice (Boulday et al., 2009, 2011; Chan et al., 2011; He et al.,
2010; Kleaveland et al., 2009; Whitehead et al., 2009, 2004). Given
that CCM1/2/3 proteins have been identiﬁed as responsible for
cerebral cavernous malformations (CCMs) (He et al., 2010; Kar
et al., 2015), a brain blood vessel assembly defect, we investigated
whether these proteins were attenuated in NgBR deﬁcient en-
dothelial cells. NgBR deﬁciency in EC decreases both transcrip-
tional and translational levels of CCM1 and CCM2 in HBMVECs
determined by real-time PCR (Fig. S10A) and Western blot analysis
(Fig. S10B). The quantiﬁcation of western blot using image J (Fig.
S10C) reiterates that lack of NgBR in HBMVECs results in loss of
CCM1 and CCM2 proteins. These results were also conﬁrmed
in vivo where genetic depletion of NgBR in EC decreases the
transcript of CCM1 and CCM2 in the yolk sac of NgBR inducible
knockout mouse embryos (Fig. S10D). To address the role of NgBR
in disease, and because we observed association with loss of NgBR
and CCM proteins in vitro and in vivo, we performed NgBR im-
munohistochemical (IHC) staining on 11 cerebral cavernous mal-
formation patient tissue samples and compared them to 6 control
tissue samples from epilepsy patients. CCM lesions were con-
ﬁrmed by H&E staining showing the thin grape-like CCM lesions
and decreased CCM2 IHC staining in CCM patient samples (Fig.
S10E). Fig. S10E shows that both NgBR and CCM2 IHC staining in
cerebral cavernous malformation BV is weaker than the control
patient BV, indicating that disease patient tissues exhibit loss of
NgBR. To quantify the expression difference, we performed CD31
and NgBR co-immunoﬂuorescence staining on these patient
samples (Fig. S10F). The intensity of NgBR IF staining in endothelial
cells was quantiﬁed using iCys software, where both CD31 and
NgBR positive signals were quantiﬁed. Fig. S10G shows that per-
centage of NgBR to CD31 ratio is decreased in CCM patient samples
as compared to control patient samples. Fig. S10H shows histo-
gram from iCys analysis reiterating that cerebral cavernous mal-
formation tissues show loss of NgBR in CD31 positive EC.
Our results identify an association between NgBR and CCM
proteins in that loss of NgBR in endothelial cells shows less CCM1
and CCM2 proteins, which are involved in the pathogenesis of
cerebral cavernous malformations (He et al., 2010; Kar et al., 2015).
CCMs disease is a common form of vascular malformation with a
prevalence of 0.1–0.5% in the human population (Al-Shahi Salman
et al., 2012; Draheim et al., 2014; Fischer et al., 2013; Haasdijk
et al., 2012). CCMs happens primarily in the brain shown as thin-
walled, dilated blood vessels (BV), which may cause seizures,
headaches and stroke in midlife and are often associated with
focal hemorrhage (He et al., 2010; Kleaveland et al., 2009;
Whitehead et al., 2004). Although signiﬁcant progress has been
made by identifying CCM family proteins (CCM1/KRIT1, CCM2,
CCM3/PDCD10), the molecular mechanism of the CCMs patho-
genesis remains to be established (Haasdijk et al., 2012). Our data
implies NgBR, a receptor for Nogo-B, as a putative new regulator in
the pathogenesis of cerebral vascular anomalies because EC
homeostasis and cerebral vascular plexus formation is disrupted in
NgBR ecKO mice. In addition, recent studies have connected Erk
and Akt phosphorylation signaling to CCM pathways (Dibble et al.,
2010; Ma et al., 2007; Schleider et al., 2011; Wilhelm et al., 2006).
Since in vitro results show that NgBR deﬁciency can hinder phos-
phorylation of Akt and Erk in HBMVECs (Fig. S9B and C), NgBR
could be a potential player in CCM pathways. In addition, our in
vitro and in vivo results (Fig. S10A–D) demonstrated that loss of
NgBR expression in brain EC decreased the RNA and protein levels
of CCM1 and CCM2. Based on a Knudson's two-hit hypothesis in
CCM pathogenesis (Gault et al., 2005; Fischer et al., 2013), the
initiation of cavernous malformation would require subsequent
loss of both CCM gene alleles in individual cells. Loss of one allele
in all cells (germline mutation, ﬁrst hit) would be followed in some
cells by a somatic mutation or expression loss in the other allele
U. Rana et al. / Developmental Biology 410 (2016) 190–201200(second hit). The causes of the second hit remain are still unclear
(Fischer et al., 2013). Our results in Fig. S10E–H have shown that
CCM disease patients may exhibit signiﬁcant loss of NgBR in EC.
Our ﬁndings implicate that loss of NgBR in EC may be the one of
factors leading to the second hit of causing the decreased ex-
pression of CCM1 and CCM2 genes. However, the link between
vascular lesions presented in NgBR ecKO mice to the CCM patho-
genesis needs to be further investigated.5. Conclusions
In summary, the cerebral vasculature defects observed in NgBR
mutant embryos demonstrated the important roles of NgBR in
regulating cerebral blood vessel assembly and pathophysiology of
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